In vitro and in vivo evaluation of novel chromeno[2,3-d]pyrimidinones as therapeutic agents for triple negative breast cancer.
Carvalho L, de Lima FP, Cerqueira M, Silva A, Pontes O, Oliveira-Pinto S, Guerreiro S, Costa MD, Granja S, Maciel P, Longatto-Filho A, Baltazar F, Proença F, Costa M.
Carvalho L, et al. Among authors: maciel p.
RSC Med Chem. 2024 Mar 19;15(4):1362-1380. doi: 10.1039/d3md00682d. eCollection 2024 Apr 24.
RSC Med Chem. 2024.
PMID: 38665823